Your chance to get on the next “60-Second Trade”

Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!

Alfred J. Ford, Jr. net worth and biography

Alfred Ford, Jr. Biography and Net Worth

Insider of Axonics

Alfred J. Ford Jr. serves as Chief Commercial Officer of the Company. From January 1997 to June 2017, Mr. Ford served as President and Chief Commercial Officer, General Manager, Vice President, Global Sales & Marketing, Vice President, Sales, Distribution Director, Regional Sales Manager and Territory Manager of Cardiac Science, Inc., a manufacturer of external automatic defibrillators. Mr. Ford holds a B.S. in Marketing and a M.S. in International Marketing from Saint Joseph’s University.

What is Alfred J. Ford, Jr.'s net worth?: The estimated net worth of Alfred J. Ford, Jr. is at least $2.45 million as of August 15th, 2023. Mr. Ford, Jr. owns 34,565 shares of Axonics stock worth more than $2,453,424 as of December 26th. This net worth evaluation does not reflect any other investments that Mr. Ford, Jr. may own. Learn More about Alfred J. Ford, Jr.'s net worth.
How do I contact Alfred J. Ford, Jr.?: The corporate mailing address for Mr. Ford, Jr. and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (949) 396-6322 and via email at [email protected]. Learn More on Alfred J. Ford, Jr.'s contact information.
Has Alfred J. Ford, Jr. been buying or selling shares of Axonics?: Alfred J. Ford, Jr. has not been actively trading shares of Axonics during the last quarter. Most recently, Alfred J. Ford, Jr. sold 14,769 shares of the business's stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $62.34, for a transaction totalling $920,699.46. Following the completion of the sale, the insider now directly owns 34,565 shares of the company's stock, valued at $2,154,782.10. Learn More on Alfred J. Ford, Jr.'s trading history.
Who are Axonics' active insiders?: Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (Co-Founder, Chief Executive Officer and Director), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Kari Keese (CFO), Jane Kiernan (Director), Esteban Lopez (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.
Are insiders buying or selling shares of Axonics?: During the last year, insiders at the sold shares 8 times. They sold a total of 92,797 shares worth more than $6,275,226.67. The most recent insider tranaction occured on October, 2nd when CFO Kari Leigh Keese sold 2,961 shares worth more than $205,523.01. Insiders at Axonics own 1.9% of the company. Learn More about insider trades at Axonics.
Information on this page was last updated on 10/2/2024.

Alfred J. Ford, Jr. Insider Trading History at Axonics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/15/2023	Sell	14,769	$62.34	$920,699.46	34,565
7/28/2023	Sell	1,500	$62.01	$93,015.00	49,334
1/31/2023	Sell	6,234	$61.15	$381,209.10	54,539
1/13/2023	Sell	36,015	$66.40	$2,391,396.00	36,773
4/19/2021	Sell	54,296	$58.56	$3,179,573.76	28,595
2/1/2021	Sell	1,883	$51.42	$96,823.86	10,273
1/26/2021	Sell	2,417	$53.58	$129,502.86	7,065
9/2/2020	Sell	37,667	$40.38	$1,520,993.46
8/31/2020	Sell	2,667	$42.31	$112,840.77

Alfred J. Ford, Jr. Buying and Selling Activity at Axonics

Axonics Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Today's Range

Now: $70.98

$70.37

$71.05

50 Day Range

MA: $70.61

$69.66

$70.98

2 Week Range

Now: $70.98

$55.09

$71.05

Volume

4,233,300 shs

Average Volume

713,457 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

How Low-Cost Stocks Generate Monthly Income

From Darwin | Ad

Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!

👉 Yes, I Want the Free Report! 👈